Adipotide 10 mg

Dragon Pharma Adipotide 10 mg

Stubborn fat remains one of the most difficult challenges in physique development, especially when traditional diet and training approaches reach their limits. Dragon Pharma Adipotide 10 mg is a research-grade peptide developed to study a fundamentally different approach to fat reduction. Instead of influencing appetite or metabolic rate, Adipotide targets the vascular support of white adipose tissue itself. When you choose to Buy Adipotide by Dragon Pharma, you are selecting a specialized research compound produced under strict quality standards by a Legit Dragon Pharma source.

Adipotide Mechanism of Action

Adipotide, also known as Prohibitin-Targeting Peptide-1 (FTPP), is a synthetic peptidomimetic composed of two functional components. The first is a homing sequence that selectively binds to receptors expressed on endothelial cells supplying white adipose tissue. The second component is a pro-apoptotic peptide sequence. Once bound and internalized, Adipotide disrupts mitochondrial function within these endothelial cells, triggering programmed cell death. As blood supply to the fat cells is reduced, the adipocytes are gradually eliminated and cleared by the body.

Bodybuilding & Aesthetic Research Benefits

From a physique and body composition research perspective, Adipotide is unique. Unlike caloric restriction or stimulant-based fat loss compounds, its action is localized to fat tissue vasculature rather than muscle or central nervous system pathways. In non-human primate studies, weight loss occurred primarily through fat mass reduction rather than muscle or water loss. This makes Adipotide of particular interest for studying stubborn, diet-resistant fat deposits that often obscure muscle definition during cutting phases.

Metabolic & Glucose Research

Adipose tissue plays a major role in insulin sensitivity and metabolic regulation. Research suggests that Adipotide administration may rapidly improve glucose tolerance and insulin responsiveness, sometimes occurring before visible fat loss. These effects are believed to be linked to reduced adipose inflammation and changes in adipokine signaling. For researchers studying metabolic health during intensive training or post-cycle recovery, Adipotide provides insight into the relationship between fat vasculature and glucose regulation.

Therapeutic Research Background

Adipotide was originally developed as an experimental therapy for obesity, designed to overcome limitations of appetite suppressants and absorption inhibitors. By directly reducing vascular support to fat tissue, it represents a non-surgical strategy for adipose reduction. Additionally, because prohibitin receptors are overexpressed in certain tumor vasculature, Adipotide has also been investigated in oncology research for its potential anti-angiogenic properties.

Dosage (Men)

Research protocols for male subjects commonly range between 0.5 mg and 1.5 mg administered subcutaneously per day. Due to its potency, study durations are typically short, often 2–4 weeks, followed by a washout period of equal length. Conservative dosing and careful monitoring are recommended.

Dosage (Women)

Female research models generally utilize lower daily doses, commonly ranging from 0.3 mg to 0.8 mg administered subcutaneously. As with male protocols, cycles are usually limited to 2–4 weeks, with emphasis on tolerance assessment and recovery.

Active Life

While Adipotide is cleared from circulation relatively quickly, its biological effects accumulate over time. Fat reduction occurs gradually as the body clears apoptotic cells, meaning visible changes may continue even after administration has ended.

Adipotide Side Effects

In animal studies, the primary observed concern was a reversible, dose-dependent impact on renal proximal tubule function. For this reason, kidney markers and hydration status are important monitoring points in research settings. Additional mild effects may include injection site irritation, transient fatigue, or nausea during active study phases.

Contraindications & Precautions

Adipotide should not be used in research models with pre-existing kidney dysfunction. Adequate hydration is essential throughout the study period. This compound is intended strictly for laboratory research and is not for human consumption. Pregnant or nursing individuals should avoid handling the compound.

Overdosage

Excessive dosing may increase renal stress and accelerate fat cell apoptosis beyond the body's clearance capacity. There is no known antidote; discontinuation and supportive monitoring of renal and hepatic markers is advised.

Adipotide Stack / Cycle Research

In metabolic and body composition studies, Adipotide is often combined with complementary compounds. A common research stack includes AOD 9604 to support lipolysis, GW501516 to enhance fatty acid utilization, and L-Carnitine 500 to assist lipid transport and cellular energy. Typical study cycles last 4 weeks, followed by a 4-week washout.

Package Presentation

Adipotide 10 mg is supplied in a sealed, sterile 2 mL clear glass vial containing a white to off-white lyophilized powder. Each vial is labeled with batch information and expiration date to ensure traceability and authenticity.

Storage

Store unopened vials in a cool, dry environment away from light. Refrigeration is recommended for extended storage. After reconstitution, keep refrigerated and use within 28 days to maintain stability.

Adipotide Referrers

Adipotide's mechanism and outcomes have been documented in peer-reviewed literature. Foundational research published in Science Translational Medicine demonstrated significant fat loss and improved insulin sensitivity in obese primates. Additional comparative research has evaluated peptide-based vascular targeting strategies. Read the comparative study on PubMed.